This Asia meeting 2024 will bring together industry, regulatory authorities, and academia to address pressing challenges in public health and drug development in Asia. The event will feature sessions where speakers will discuss recent advancements in regulatory science and the use of innovative tools to expedite clinical development and pharmacovigilance (PV).
One key topic will focus on regulatory agencies’ perspectives, highlighting recent advances in regulatory science and how the medical and regulatory landscapes are evolving. Speakers will also explore areas ripe for innovation in regulatory science.
Another topic will delve into the impact of real-world data (RWD) on regulatory decision-making, featuring case studies showcasing RWD’s role in indication expansion, new drug approvals, and post-marketing studies. Speakers will assess data quality, integration, analysis methods, and practical considerations.
Additionally, experts from the pharmaceutical industry will discuss the latest developments and practical applications of AI in clinical development. Topics will include indication selection, patient enrichment, AI-supported diagnosis, operational excellence, and AI-powered medical writing.
Lastly, This event will explore the integration of AI technologies in safety surveillance, signal detection, and risk management in pharmaceuticals. Attendees will gain insights into leveraging AI for enhanced patient safety outcomes through collaboration and knowledge-sharing.

View Program